Activity of T-DXd in HER2-expressing Biliary Tract Cancer
Paolo Tarantino shared on X:
“Activity of T-DXd in HER2-expressing BTC published in Journal of Clinical Oncology. ORR 36% in HER2+ BTC, with most durable responses in HER2 IHC 3+. Little activity in HER2-low BTC (ORR 12%). High rate of ILD (25%), with 2 deaths. Careful ILD monitoring required with T-DXd! ”
Authors: Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto, Yoshito Komatsu, Makoto Ueno, Satoshi Kobayashi, Masafumi Ikeda, Mitsuhito Sasaki, Junji Furuse, Naohiro Okano, Nobuyoshi Hiraoka, Hiroshi Yoshida, Aya Kuchiba, Ryo Sadachi, Kenichi Nakamura,Naoko Matsui, Yoshiaki Nakamura, Wataru Okamoto, Takayuki Yoshino, and Takuji Okusaka.
Source: Paolo Tarantino/X
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023